NanoBio’s Intranasal Vaccine Demonstrates Robust Protection Against Herpes Simplex-2 Infection
Comments Off on NanoBio’s Intranasal Vaccine Demonstrates Robust Protection Against Herpes Simplex-2 InfectionANN ARBOR, Mich., (April 28, 2014) – NanoBio Corporation today announced that the company will present new data at the National Foundation for Infectious Diseases’ 17th Annual Conference on Vaccine Research (NFID ACVR ), demonstrating the benefits of its nanoemulsion (NE) adjuvant in the development of an intranasal herpes simplex virus-2 (HSV-2) vaccine. (more…)